Vir Biotechnology (VIR) is advancing its ECLIPSE phase 3 program for tobevibart + elebsiran in Hepatitis Delta Virus, with topline data from all 3 studies expected Q1 2027. Company's dual-masked ...
(MENAFN- EIN Presswire) EINPresswire/ -- Goody PR agency is honored to receive two top 2025 MarCom Awards – Platinum level for two categories: 1. Best Public Relations Program and 2. Best Publicity ...